This educational Mini Module will explain practical, clinically applicable approaches for minimizing and managing adverse events associated with CFTR modulators and for optimizing adherence.
Release Date: March 8, 2018
Expiration Date: February 28, 2019
This activity is intended for physicians, physician assistants, nurse practitioners, nurses, and pharmacists who actively treat/manage patients with cystic fibrosis.
Upon completion of this enduring material, participants should be able to:
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Review all modules associated with this course.
- Successfully complete the post-test ( accuracy).
- Complete the CME/CE evaluation.
- The estimated time to complete this activity is hour.
- Upon successful completion, your CME/CNE certificate will be emailed to you. CPE credit will be submitted to the Rush University Medical Center and posted to CPE Monitor.
In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.
Rush University Medical Center designates this live activity for a maximum of AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is contact hours.
This knowledge-based activity is accredited for hour of continuing pharmacy education (CPE) credit. Duquesne University School of Pharmacy will report all credit to CPE Monitor within 60 working days after receiving evidence of successful completion of the course. Successful completion includes achieving a score of at least on the test and a completed evaluation.
Duquesne University School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (UAN # ). Participation in the entire knowledge-based activity is required to obtain a certificate. This activity is being presented without bias and with commercial support.
Effective January 1, 2012, all pharmacists are required to provide their NABP e-Profile ID # and Date of Birth (in MMDD format) for issuance of CE credits for any ACPE-accredited CPE sessions. Please go to the following website for full details: https://nabp.pharmacy/cpe-monitor-service.
Participation in the entire knowledge-based activity is required to obtain a certificate. This activity is being presented without bias and with commercial support.
RESOLUTION OF CONFLICT OF INTEREST
In accordance with the ACCME Standards for Commercial Support of CME, the Rush University Medical Center and Practice Point Communications will implement mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.
All planners and faculty participating in continuing education activities provided by the Rush University Medical Center are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. A commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the Rush University Medical Center.
The following indicates the disclosure declaration information and the nature of those commercial relationships.
The speakers and planning committee members listed below have stated they have no significant relationships to disclose.
Robert Balk, MD
Beth-Anne M. Christopher, MS, RN, CNL
Suzanne Higginbotham, BS, PharmD, BCACP
The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information they planned and/or present is done so fairly and without bias:
Clement L. Ren, MD, MBA
Employment (includes retainer): None
Industry funded research/investigator: None
Speakers Bureau, Faculty, Peer Reviewer: None
Advisory Committee/Board: None
Patent holder: None
Other (please describe): None
Plan to discuss investigational/off-label uses of drugs or devices? (Y/N): N
The Rush University Medical Center, Duquesne University School of Pharmacy and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center, Duquesne University School of Pharmacy and Practice Point Communications assume no liability for the information herein.
The Rush University Medical Center, Duquesne University School of Pharmacy and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center, Duquesne University School of Pharmacy and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.
Rush University Medical Center, Duquesne University School of Pharmacy and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
- Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
- Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
- Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.
- Windows XP or above running Internet Explorer 7 (service pack 2) or above.
- MAC OSX 10.5 (Leopard) or above running Safari 5.1 or above, or any version of Chrome, Firefox or Opera published in the last two years.
- A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.
- Any Apple iPad or iPad Mini running iOS 5 or above.
- Most high-performance Android tablets such as the Kindle Fire or Samsung Galaxy S.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
Supported by an independent educational grant from Vertex Pharmaceuticals.